Skip to main content
OpenTrials
Completed

NCT Number: NCT06231862

Gene Expression Objective Definition of Early Sepsis In Children

GEODESIC is a prospective descriptive cohort investigation that will examine the generalizability of the novel host gene expression biomarkers, SeptiCyteTM LAB, SeptiCyteTM VIRUS, SeptiCyteTM BACT, and SeptiCyteTM TRIAGE (collectively 18 genes or SeptiCyteTM LVBT) and SeptiCyteTM RAPID, for differentiating children with bacterial sepsis, versus severe viral illness, versus non-infectious related systemic inflammatory response syndrome.

Completed

Looking for future studies?

Notify Me

Key information

Age range

1 month–17 year

Sex eligibility

All sexes

Study type

Observational

Primary location

Seattle Children's Hospital, Seattle, Washington, United States

Loading trial locations.

About this study

Specific Aim 1. Validate the robustness of the SeptiCyteTM LVBT gene expression signatures for providing clear discrimination between critically ill children with bacterial sepsis versus severe viral illness versus infection-negative systemic inflammation (INSI) secondary to a variety of etiologies.

Approach: We will expand our previous Genotypes And Phenotypes in Pediatric SIRS and Sepsis (GAPPSS) INSI cohort to children with recent trauma, thermal burns, anoxic-ischemic reperfusion events, exposure to cardiopulmonary bypass, extracorporeal life support, or dialytic therapy, CAR-T cell therapy, and various rheumatologic diagnoses. e we will recruit children with bacterial and viral infection who demonstrate a spectrum of illness severity and organ dysfunction. This specific aim will demonstrate the generalizability of SeptiCyteTM LVBT among critically children with life-threatening infectious disease or INSI.

Specific Aim 2. Determine if SeptiCyteTM LVBT gene expression signatures trend towards resolution of previously induced or suppressed gene expression states as critical illness resolves.

Approach: We will obtain paired blood samples for SeptiCyteTM LVBT gene expression, the first around the time of intensive care unit (ICU) admission (critically ill) and the second at ICU discharge approximately 48 hours later (transition to acute care). Resolution of critical illness will be quantified by serial daily measures of composite organ dysfunction.

Specific Aim 3. Ascertain that performance of SeptiCyteTM RAPID utilizing a point of care device at Seattle Children's will be equivalent to centralized assessment using SeptiCyteTM LAB.

Approach: Blood samples will be processed on site (Seattle Children's) for SeptiCyte RAPID testing. SeptiCyteTM RAPID is the result of the translation of the SeptiCyteTM LAB test to the cartridge-based Biocartis Idylla™ platform.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

INSI Cohort

  • Admitted to the PICU
  • New severe trauma OR
  • New thermal burns OR
  • Rheumatologic diagnoses OR
  • Post-initiation (or circuit change) of extracorporeal life support OR
  • Post anoxic-ischemic-reperfusion insults OR
  • Infants undergoing cardiac surgery with cardiopulmonary bypass OR
  • CAR-T cell therapy
  • Parents speak English or Spanish AND
  • Not previously enrolled in the GEODESIC investigation

Pediatric Bacterial Sepsis Cohort

  • Admitted to the PICU
  • Parents speak English or Spanish AND
  • Exhibit SIRS criteria including at least fever/hypothermia or leukocytosis/leukopenia or left shift on the leukocyte differential AND
  • Strongly suspected or documented source of bacterial infection per primary care team
  • Not previously enrolled in the GEODESIC investigation

Pediatric Bacterial Sepsis Cohort

  • Admitted to the PICU
  • Parents speak English or Spanish AND
  • Positive PCR or culture verifying a viral infection
  • Not previously enrolled in the GEODESIC investigation

Exclusion criteria

  • Not expected to survive the PICU stay
  • Child has 'ward of the state' status

Treatment and study plan

SeptiCyte (various)

Diagnostic Test

mRNA expression scores

Primary outcomes

  1. mRNA expression

    Time frame: At PICU admission and 48 hours later

    SeptiCyte (various) gene expression scores

Sponsors and collaborators

Lead sponsor

Seattle Children's Hospital

Other

Collaborators

  • Immunexpress

Registry information

Acronym: GEODESIC

Important dates

Study start
2019
Primary completion
2023
Study completion
2023
First posted
Jan 30, 2024
Registry last updated
Jan 30, 2024

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.